Lin Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lin Zhu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Andrew Hayen
School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia
5 shared publications- Fuzhong Xue
Department of Medical Dataology, School of Public Health, Cheeloo College of Medicine, Shandong University, China
3 shared publications Katy J.L. Bell
School of Public Health, The University of Sydney, Camperdown, New South Wales, Australia
3 shared publications- Paul Glasziou
Institute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia
3 shared publications - Yanxun Liu
Department of Epidemiology and Biostatistics, School of Public Health, Shandong University, Jinan 250012, China
3 shared publications Agnish Nayak
Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Elsevier in Kidney International
- Vol. 110 (1) , 78-88
Advances in survival analyses: machine learning methods and model comparison
- 29 April 2026
- Published by Elsevier in Kidney International
- Vol. 110 (1) , 78-88
Open AccessAdvances in survival analyses: machine learning methods and model comparison
- 17 September 2025
- Published by Elsevier in Kidney International
- Vol. 109 (3) , 421-423
Causal inference using regression discontinuity analysis: what can the nephrologist learn from herpes zoster vaccination?
- 17 September 2025
- Published by Elsevier in Kidney International
- Vol. 109 (3) , 421-423
Causal inference using regression discontinuity analysis: what can the nephrologist learn from herpes zoster vaccination?
- 7 June 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 160, 110-116
Methods to address selection bias in post-trial studies of legacy effects were evaluated
- 7 June 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 160, 110-116
Methods to address selection bias in post-trial studies of legacy effects were evaluated
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S464
Abstract 1542: ATP10A has a protective and sex-specific role in lipid metabolism
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S464
Open AccessAbstract 1542: ATP10A has a protective and sex-specific role in lipid metabolism
- 1 November 2022
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 182 (11) , 1233-1234
Keeping Score—Appropriate and Timely Use of CACS—Reply
In Reply Contrary the suggestion made by Drs Otton and Hamilton-Craig, our evaluation of the incremental value of coronary artery calcium score (CACS)1 did not exclude intermediate risk, but rather included studies reporting across the risk spectrum. We did exclude studies that reported only on a single risk stratum. As previously explained in a separate article,2 restricting analysis to a single risk group is misleading because it artifactually overestimates the gain in C-statistic. The apparent discriminative ability of the risk equation within a restricted risk range (1 risk stratum) appears worse than for the full population (all risk strata). This artifactually inflates the apparent gain in C-statistic by CACS within each risk stratum (low, intermediate, or high risk)—a statistical artifact, not a true gain. As evidence of the large clinical importance of CACS, Drs Otton and Hamilton-Craig cite an earlier report from the Multi-Ethnic Study of Atherosclerosis in which more than one-quarter of patients screened with CACS were reclassified across treatment thresholds. However, showing that patients were reclassified is insufficient; the reclassification actually needs to be correct. The reclassification results of that report were similar to those of a more recent Multi-Ethnic Study of Atherosclerosis report included in our review,1 in which 87% (496 of 572) of patients newly classified as having a 7.5% or greater 10-year risk did not have an event during the follow-up period (mean, 10 years). Drs Otton and Hamilton-Craig further argue that this was not unexpected and that up to 92.5% of individuals in this risk class were expected to remain event free. However, this would only be true if most individuals had only a small change in risk with the addition of CACS, ie, most newly classified intermediate- to high-risk patients were only slightly higher than the 7.5% risk threshold. We did not have individual patient data to directly investigate this scenario, but it is supported by the very high proportion (85.5%-96.4%) of the newly classified individuals in our review who did not have an event. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- 1 November 2022
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 182 (11) , 1233-1234
Keeping Score—Appropriate and Timely Use of CACS—Reply
In Reply Contrary the suggestion made by Drs Otton and Hamilton-Craig, our evaluation of the incremental value of coronary artery calcium score (CACS)1 did not exclude intermediate risk, but rather included studies reporting across the risk spectrum. We did exclude studies that reported only on a single risk stratum. As previously explained in a separate article,2 restricting analysis to a single risk group is misleading because it artifactually overestimates the gain in C-statistic. The apparent discriminative ability of the risk equation within a restricted risk range (1 risk stratum) appears worse than for the full population (all risk strata). This artifactually inflates the apparent gain in C-statistic by CACS within each risk stratum (low, intermediate, or high risk)—a statistical artifact, not a true gain. As evidence of the large clinical importance of CACS, Drs Otton and Hamilton-Craig cite an earlier report from the Multi-Ethnic Study of Atherosclerosis in which more than one-quarter of patients screened with CACS were reclassified across treatment thresholds. However, showing that patients were reclassified is insufficient; the reclassification actually needs to be correct. The reclassification results of that report were similar to those of a more recent Multi-Ethnic Study of Atherosclerosis report included in our review,1 in which 87% (496 of 572) of patients newly classified as having a 7.5% or greater 10-year risk did not have an event during the follow-up period (mean, 10 years). Drs Otton and Hamilton-Craig further argue that this was not unexpected and that up to 92.5% of individuals in this risk class were expected to remain event free. However, this would only be true if most individuals had only a small change in risk with the addition of CACS, ie, most newly classified intermediate- to high-risk patients were only slightly higher than the 7.5% risk threshold. We did not have individual patient data to directly investigate this scenario, but it is supported by the very high proportion (85.5%-96.4%) of the newly classified individuals in our review who did not have an event. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- Open Access
- 22 April 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 876166
Antimicrobial Photodynamic Therapy Involving a Novel Photosensitizer Combined With an Antibiotic in the Treatment of Rabbit Tibial Osteomyelitis Caused by Drug-Resistant Bacteria
Osteomyelitis is deep tissue inflammation caused by bacterial infection. If such an infection persists, it can lead to dissolution and necrosis of the bone tissue. As a result of the extensive use of antibiotics, drug-resistant bacteria are an increasingly common cause of osteomyelitis, limiting the treatment options available to surgeons. Photodynamic antibacterial chemotherapy has attracted increasing attention as a potential alternative treatment. Its advantages are a broad antibacterial spectrum, lack of drug resistance, and lack of toxic side effects. In this study, we explored the impact of the new photosensitizer LD4 in photodynamic antimicrobial chemotherapy (PACT), both alone and in combination with an antibiotic, on osteomyelitis. A rabbit tibial osteomyelitis model was employed and microbiological, histological, and radiological studies were performed. New Zealand white rabbits (n = 36) were randomly divided into a control group, antibiotic group, PACT group and PACT + antibiotic group for treatment. In microbiological analysis, a reduction in bacterial numbers of more than 99.9% was recorded in the PACT group and the PACT + antibiotic group 5 weeks after treatment (p < 0.01). In histological analysis, repair of the damaged bone tissue was observed in the PACT group, and bone repair in the PACT + antibiotic group was even more significant. In radiological analysis, the X-ray Norden score showed that the severity of bone tissue defects or destruction followed the pattern: PACT + antibiotic group < PACT group < antibiotic group < control group.
- 22 April 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 876166
Open AccessAntimicrobial Photodynamic Therapy Involving a Novel Photosensitizer Combined With an Antibiotic in the Treatment of Rabbit Tibial Osteomyelitis Caused by Drug-Resistant Bacteria
Osteomyelitis is deep tissue inflammation caused by bacterial infection. If such an infection persists, it can lead to dissolution and necrosis of the bone tissue. As a result of the extensive use of antibiotics, drug-resistant bacteria are an increasingly common cause of osteomyelitis, limiting the treatment options available to surgeons. Photodynamic antibacterial chemotherapy has attracted increasing attention as a potential alternative treatment. Its advantages are a broad antibacterial spectrum, lack of drug resistance, and lack of toxic side effects. In this study, we explored the impact of the new photosensitizer LD4 in photodynamic antimicrobial chemotherapy (PACT), both alone and in combination with an antibiotic, on osteomyelitis. A rabbit tibial osteomyelitis model was employed and microbiological, histological, and radiological studies were performed. New Zealand white rabbits (n = 36) were randomly divided into a control group, antibiotic group, PACT group and PACT + antibiotic group for treatment. In microbiological analysis, a reduction in bacterial numbers of more than 99.9% was recorded in the PACT group and the PACT + antibiotic group 5 weeks after treatment (p < 0.01). In histological analysis, repair of the damaged bone tissue was observed in the PACT group, and bone repair in the PACT + antibiotic group was even more significant. In radiological analysis, the X-ray Norden score showed that the severity of bone tissue defects or destruction followed the pattern: PACT + antibiotic group < PACT group < antibiotic group < control group.
- Open Access
- 13 April 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 416
Analyses within risk strata overestimate gain in discrimination: the example of coronary artery calcium scores
Risk prediction models are potentially useful tools for health practitioners and policy makers. When new predictors are proposed to add to existing models, the improvement of discrimination is one of the main measures to assess any increment in performance. In assessing such predictors, we observed two paradoxes: 1) the discriminative ability within all individual risk strata was worse than for the overall population; 2) incremental discrimination after including a new predictor was greater within each individual risk strata than for the whole population. We show two examples of the paradoxes and analyse the possible causes. The key cause of bias is use of the same prediction model as for both stratifying the population, and as the base model to which the new predictor is added.
- 13 April 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 416
Open AccessAnalyses within risk strata overestimate gain in discrimination: the example of coronary artery calcium scores
Risk prediction models are potentially useful tools for health practitioners and policy makers. When new predictors are proposed to add to existing models, the improvement of discrimination is one of the main measures to assess any increment in performance. In assessing such predictors, we observed two paradoxes: 1) the discriminative ability within all individual risk strata was worse than for the overall population; 2) incremental discrimination after including a new predictor was greater within each individual risk strata than for the whole population. We show two examples of the paradoxes and analyse the possible causes. The key cause of bias is use of the same prediction model as for both stratifying the population, and as the base model to which the new predictor is added.
- 1 March 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 131, 51-58
A methods review of posttrial follow-up studies of cardiovascular prevention finds potential biases in estimating legacy effects
- 1 March 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 131, 51-58
A methods review of posttrial follow-up studies of cardiovascular prevention finds potential biases in estimating legacy effects
- Open Access
- 12 December 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of Mind-body Exercise on PTSD Symptoms, Depression and Anxiety in PTSD Patients : A protocol of Systematic Review and Meta-Analysis
INPLASY2020120072 Effects of Mind-body Exercise on PTSD Symptoms, Depression and Anxiety in PTSD Patients : A protocol of Systematic Review and Meta-Analysis Keywords: Mind-body Exercise; PTSD Symptom; Depression; Anxiety. Download PDF – 2020120072
- 12 December 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessEffects of Mind-body Exercise on PTSD Symptoms, Depression and Anxiety in PTSD Patients : A protocol of Systematic Review and Meta-Analysis
INPLASY2020120072 Effects of Mind-body Exercise on PTSD Symptoms, Depression and Anxiety in PTSD Patients : A protocol of Systematic Review and Meta-Analysis Keywords: Mind-body Exercise; PTSD Symptom; Depression; Anxiety. Download PDF – 2020120072
- Open Access
- 5 March 2020
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 19 (1) , 1-9
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Background: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible “legacy effects” of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia. Methods: The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups. Results: 853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality (adjusted HR = 0.65, 95% CI 0.45–0.94; P = 0.02). Conclusions: Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in order to reduce cardiovascular risk in diabetic patients with dyslipidemia. Trial registration clinicaltrials.gov, Identifier: NCT00000620
- 5 March 2020
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 19 (1) , 1-9
Open AccessLegacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Background: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible “legacy effects” of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia. Methods: The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups. Results: 853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality (adjusted HR = 0.65, 95% CI 0.45–0.94; P = 0.02). Conclusions: Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in order to reduce cardiovascular risk in diabetic patients with dyslipidemia. Trial registration clinicaltrials.gov, Identifier: NCT00000620